<DOC>
	<DOCNO>NCT01643928</DOCNO>
	<brief_summary>This extension study evaluate safety ( include immunogenicity ) treatment rituximab-Pfizer , well safety immunogenicity transition rituximab-US rituximab-EU rituximab-Pfizer . This study provide continue treatment access subject active rheumatoid arthritis participate least 16 week study rituximab Pfizer program .</brief_summary>
	<brief_title>Rheumatoid Arthritis Extension Trial For Subjects Who Have Participated In Other PF-05280586 Trials ( REFLECTIONS B328-04 )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Willing able comply schedule visit , treatment plan , laboratory test , study procedure . Participated minimum 16 week initiation last course treatment previous rheumatoid arthritis study rituximabPfizer program within past 2 month . Investigational site staff member relatives site staff member subject Pfizer employee directly involve conduct study . Initiated treatment investigational agent biologics ( include Rituxan MabThera ) since participate previous rheumatoid arthritis study rituximabPfizer program .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>extension trial</keyword>
	<keyword>rheumatoid arthritis</keyword>
	<keyword>rituximab</keyword>
</DOC>